Clinical Research Directory

Inclusion Criteria: 1. Male or female patients aged from 18 to 70 years old; 2. The patient's ECOG score is ≤ 2; 3. Patients with advanced or metastatic renal cell carcinoma: (1) have received first-line and second-line targeted therapy in the past; (2) Previous immunization with PD-1/L1 and ≤2 regimens; (3) Unable to tolerate targeted therapy or immunotherapy. 4.There are measurable or evaluable lesions; 5.The main tissues and organs of patients function well: 1. liver function: ALT/AST\< 3 times the upper limit of normal value (ULN); 2. Renal function: creatinine \< 220 μmol/L; 3. Lung function: indoor oxygen saturation ≥ 95%; 4. Cardiac function: Left ventricular ejection fraction (LVEF)≥40% 6.Patients or their legal guardians voluntarily participate and sign informed consent. Exclusion Criteria: 1. Infectious diseases (such as HIV, active hepatitis B or C infection, active tuberculosis, etc.); 2. Feasibility assessment and screening showed that the transfection of targeted lymphocytes was less than 10% or the amplification was insufficient (\< 5 times) under the co-stimulation of CD3/CD28. 3. The vital signs are abnormal, and those who cannot cooperate with the examination; 4. Those who have mental or psychological diseases can not cooperate with treatment and efficacy evaluation; 5. Highly allergic constitution or severe allergic history, especially those who are allergic to IL-2; 6. Subjects with systemic infection or severe local infection who need anti-infection treatment; 7. Complicated with dysfunction of heart, lung, brain, liver, kidney and other important organs; 8. Patients with other tumors; 9. Doctors believe that there are other reasons that can not be included in the treatment.